Although earlier studies suggested that Mdm2 is the null cells in a manner reminiscent of ARF induction.
kinases (Sherr, 2001) . By virtue of its unique first exon, as a key factor in ARF-mediated p53 activation. These the ARF transcript encodes a protein that is unrelated findings identify a novel regulatory pathway that medito p16
Ink4a (Quelle et al., 1995) . Nevertheless, ARF, like ates both the p53-independent and p53-dependent tup16 Ink4a Figure 1C ). In addition, a major protein band of w500 mouse skin carcinomas through both p53-dependent kDa also copurified with ARF from HA-ARF-Flagand p53-independent pathways (Kelly-Spratt et al. the ARF-associated complexes in these cells. To elucidate the p53/Mdm2-independent functions of ARF, we purified naturally formed ARF-containing proInitial Characterization of the Ubiquitin tein complexes from p53 null human cells and identified E3 Ligase ARF-BP1 ARF-BP1, a HECT (homology to E6-AP C terminus)-Peptide sequencing of the ARF-BP1 band by mass containing ubiquitin ligase, as a major component of spectrometry identified two peptide sequences that these complexes. ARF-BP1 directly binds ARF, and its matched a single, partial cDNA clone in the GenBank ubiquitin ligase activities are strongly inhibited by ARF. database. A small fragment of this protein (named Significantly, inactivation of ARF-BP1 induces cell growth UREB1) was previously reported to bind the preprodyarrest in p53 null cells, indicating that ARF-BP1 is a norphin gene promoter, but its biological functions critical mediator of the p53-independent pathway of were not understood (Gu et al., 1994). Therefore, by ARF tumor suppression. Surprisingly, inactivation of rapid amplification of cDNA ends (RACE) and homology ARF-BP1 in p53-positive cells induces p53 stabilization alignment with the partial cDNA sequences in the dataand activates a p53-dependent apoptotic response, implying that, in addition to Mdm2, ARF-BP1 also acts base, we assembled a full-length cDNA for human ARF- BP1 cDNA (accession number AY772009). This cDNA in vitro. The ARF polypeptide can be roughly divided into two major functional domains: an N-terminal region encodes a protein of 4374 amino acids (Figure 2A and Figure S1 in the Supplemental Data available with this encoded by the unique 1β exon (N-ARF; residues 1-64), which is critical for ARF-mediated p53 activation as article online), which is more than 3000 residues longer than the published UREB1 sequence (Gu et al., 1994).
well as p53-independent ARF functions, and a C-terminal region (C-ARF; residues 65-132), which is not The C-terminal sequences of ARF-BP1 possess a signature motif (the HECT domain) common to a numconserved between human and mouse counterparts and is of uncertain function. As shown in Figure 3A , ber of ubiquitin E3 ligases (Figures 2A and 2B ). This motif was first identified in E6-AP, a cellular E3 ligase 35 S-labeled ARF-BP1 (1-1014), a polypeptide comprising the N-terminal 1014 residues of ARF-BP1, did not that, when bound to the E6 protein of oncogenic human papillomaviruses, acquires the ability to bind and ubiqassociate with immobilized GST-ARF (lanes 7-9, Figure  3A ). In contrast, however, Figure 4D , ARF expression induced G2/M accumulation of these cells, but no obvious apoptotic cells (Sub-G1) were observed ("iii" versus "i" in Figure 4D ). Strikingly, inactivation of ARF-BP1 by ARF-BP1 RNAi in these cells also led to G2/M arrest at similar levels ("ii" in Figure 4D ). Thus, inactivation of Figure 5C ). These data suggest that inactivation of ARF-BP1 stabilizes p53 and activates its mediated functions. null cells in a manner reminiscent of ARF induction. For this purpose, p53 null H1299 cells were transfected
The above results were unexpected given the view that Mdm2 is the primary mediator of ARF-induced p53 with either an ARF-BP1-specific (ARF-BP1-RNAi1) or a control (GFP-RNAi) siRNA. As shown in Figure 4A , the activation. To verify the specific effects induced by ARF-BP1 ablation, we performed multiple control exlevels of endogenous ARF-BP1 polypeptides were severely reduced after three consecutive transfections periments. Thus, for example, we were able to knock down endogenous ARF-BP1 expression and again ele-(upper panels, lane 3 versus lane 2) with ARF-BP1-RNAi1. As expected, the steady-state levels of p21 and vate the endogenous levels of p53 by treating cells with a siRNA (ARF-BP1-RNAi 2) that recognizes a different Mdm2, two known transcriptional targets of p53, were unaffected by ARF-BP1 ablation. Strikingly, however, region of the ARF-BP1 mRNA, but not with a point mu- Figure S9A ). By using in vitro ubiquitination assay, we have confirmed that this mutation at the shown in Figure 5E , when HCT116 parental cells and HCT116 p53 −/− cells were subjected to RNAi treatment, HECT domain abrogates the ubiquitin ligase activity of ARF-BP1 ( Figure S9B) . ARF-BP1 knockdown led to stabilization of p53 and induction of p21 in the parental cells, but not in the p53 To perform the "rescue experiments," we first conducted the RNAi assay in U2OS cells with ARF-BP1-null cells. In contrast, the levels of control proteins such as c-Myc and actin were unaffected by RNAi treatment. Figure 5D , Significantly, ARF-BP1 ablation induced apoptosis in parental HCT116 cells, but not in p53 null HCT116 deafter the ARF-BP1 RNAi1 treatment, endogenous p53 was stabilized, and p21 was activated; however, ARFrivatives ( Figure S11 ). As expected, the steady-state Figure 6B , p53 showed no effect (lanes 4 and 5). These data suggest Figure 7B and Figure S12 ). As expected, treatment with Mdm2-specific siRNAs had no effect on Since ARF-BP1 binds and ubiquitinates p53 in the absence of Mdm2, it is conceivable that the ARF/ARFp53 levels in Mdm2/p53 null cells (lane 3, Figure 7B ), confirming the specificity of p53 stabilization by ARF-BP1 interaction stabilizes p53 in an Mdm2-independent manner. To test this hypothesis, we first examined BP1 inactivation. 
RNAi1 and then tried to rescue by expressing the ARF-BP1 mutant [ARF-BP1(R)]. As indicated in

